Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: September 10, 2003
Last updated: September 27, 2013
Last verified: September 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)